



CHINA PIONEER PHARMA HOLDINGS LIMITED

中国先锋医药控股有限公司

(incorporated in the Cayman Islands with limited liability)
(於開曼群島註冊成立之有限公司)

GLOBAL OFFERING

Number of Offer Shares under the Global Offering	: 333,334,000 Shares (subject to adjustment and the Over-allotment Option)
Number of Hong Kong Offer Shares	: 33,334,000 Shares (subject to adjustment)
Number of International Offer Shares	: 300,000,000 Shares (subject to adjustment and the Over-allotment Option)
Maximum Offer Price	: HK\$5.00 per Share plus brokerage of 1%, SFC transaction 0.003% and Hong Kong Stock Exchange trading fee of 0.005% (payable in full on application, subject to refund)
Nominal value	: US\$0.01 per Share
Stock Code	: 01345

全球發售

全球發售的發售股份數目	: 333,334,000股股份(可予調整及視乎超額配股權行使與否而定)
香港發售股份數目	: 33,334,000股股份(可予調整)
國際發售股份數目	: 300,000,000股股份(可予調整及視乎超額配股權行使與否而定)
最高發售價	: 每股股份5.00港元，另加1%經紀佣金、0.003%證監會交易徵費及0.005%香港聯交所交易費(須於申請時繳足，可予以退還)
面值	: 每股股份0.01美元
股份代號	: 01345

Please read carefully the prospectus of China Pioneer Pharma Holdings Limited (the "Company") dated 24 October 2013 (the "Prospectus") (in particular, the section on "How to apply for Hong Kong Offer Shares" in the Prospectus) and the guide on the back of this Application Form before completing this Application Form. Terms defined in the Prospectus shall have the same meaning when used in this Application Form unless defined herein.

Hong Kong Exchanges and Clearing Limited, The Stock Exchange of Hong Kong Limited (the "Stock Exchange") and Hong Kong Securities Clearing Company Limited ("HKSCC") take no responsibility for the contents of this Application Form, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of this Application Form.

A copy of this Application Form, together with a copy of each of the WHITE and YELLOW Application Forms, the Prospectus and the other documents specified in the section headed "Documents Delivered to the Registrar of Companies and Available for Inspection" in Appendix V to the Prospectus have been registered by the Registrar of Companies in Hong Kong as required by section 342C of the Companies Ordinance. The Securities and Futures Commission in Hong Kong (the "SFC") and the Registrar of Companies in Hong Kong take no responsibility as to the contents of any of these documents.

Your attention is drawn to the paragraph headed "Personal Information Collection Statement" which sets out the policies and practices of the Company and its Hong Kong Share Registrar in relation to personal data and compliance with the Personal Data (Privacy) Ordinance.

The information contained in this Application Form is not for distribution, directly or indirectly, in or into the United States (including its territories and dependencies, any State of the United States and the District of Columbia). These materials do not constitute or form a part of any offer or solicitation to purchase or subscribe for securities in the United States. The Shares mentioned herein have not been, and will not be, registered under the United States Securities Act of 1933 as amended (the "Securities Act").

The Shares may not be offered or sold in the United States except pursuant to registration or an exemption from the registration requirements of the Securities Act. No public offering of the securities will be made in the United States.

This Application Form and Prospectus may not be forwarded or distributed or reproduced (in whole or in part) in any manner whatsoever in any jurisdiction where such forwarding, distribution or reproduction is not permitted under the law of that jurisdiction. This Application Form and Prospectus are addressed to you personally. Any forwarding, distribution or reproduction of this Application Form or the Prospectus in whole or in part is unauthorised.

To: China Pioneer Pharma Holdings Limited
UBS AG, Hong Kong Branch
The Hong Kong Underwriters

在填寫本申請表格前，請細閱中国先锋医药控股有限公司(「本公司」)於二零一三年十月二十四日刊發的招股章程(「招股章程」)，尤其是招股章程「如何申請香港發售股份」一節，及刊於本申請表格背面的指引。除另有界定者外，本申請表格所使用的詞語與招股章程所界定者具相同涵義。

香港交易及結算所有限公司、香港聯合交易所有限公司(「聯交所」)及香港中央結算有限公司(「香港結算」)對本申請表格內容概不負責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不就因本申請表格全部或任何部分內容而產生或因依賴該等內容而引發的任何損失承擔任何責任。

本申請表格連同白色及黃色申請表格、招股章程及招股章程附錄五內「送呈公司註冊處處長及備查文件」一節所列的其他文件，已遵照香港《公司條例》第342C條的規定，送呈香港公司註冊處處長註冊。香港證券及期貨事務監察委員會(「證監會」)和香港公司註冊處處長對任何此等文件的內容概不負責。

閣下敬請留意「個人資料收集聲明」一段，當中載有本公司及其香港證券登記處有關個人資料及遵守個人資料(私隱)條例的政策及常規。

本申請表格所載資料，不得在或向美國(包括其領土及屬地、美國各州及哥倫比亞特區)境內直接或間接分發。該等資料並不構成或成為在美國購買或認購證券之任何要約或徵求的一部分。本申請表格所述股份並未且不會根據一九三三年美國證券法(以修訂本為準)(「證券法」)登記。

除非已進行登記或獲豁免遵守證券法之登記規定，否則不得於美國發售或出售股份。證券不會在美國公開發售。

在任何根據有關法律不得發送、分發或複製本申請表格及招股章程之司法權區內，本申請表格及招股章程概不得以何方式發送或分發或複製(全部或部分)。本申請表格及招股章程僅致予閣下本人。概不得發送或分發或複製本申請表格或招股章程之全部或部分。

致：中国先锋医药控股有限公司
UBS AG香港分行
香港包銷商

I We confirm that we have (i) complied with the Guidelines for Electronic Public Offerings and the Operational Procedures for White Form eIPO Applications submitted via Banks/Stockbrokers and all applicable laws and regulations (whether statutory or otherwise) in relation to the provision of our White Form eIPO services in connection with the Hong Kong Public Offering; and (ii) read the terms and conditions and application procedures set out in the Prospectus and this Application Form and agree to be bound by them. Applying on behalf of each of the underlying applicants to whom this application relates, we:

吾等確認，吾等已(i)遵守電子公開發售指引及透過銀行/股票經紀遞交白表eIPO申請的運作程序以及與吾等就香港公開發售提供白表eIPO服務有關的所有適用法例及規例(法定或其他)；及(ii)閱讀招股章程及本申請表格所載的條款及條件及申請手續，並同意受其約束。為代表與本申請有關的每一相關申請人作出申請，吾等：

- apply for the number of Hong Kong Offer Shares set out below, on the terms and conditions of the Prospectus and this Application Form, and subject to the Articles of Association;
- enclose payment in full for the Hong Kong Offer Shares applied for, including 1% brokerage fee, 0.003% SFC transaction levy and 0.005% Stock Exchange trading fee;
- confirm that the underlying applicants have undertaken and agreed to accept the Hong Kong Offer Shares applied for, or any lesser number allocated to such underlying applicants on this application;
- understand that these declarations and representations will be relied upon by the Company, the Sole Sponsor, the Sole Global Coordinator, the Joint Bookrunners, the Joint Lead Managers and the Underwriters in deciding whether or not to make any allotment of Hong Kong Offer Shares in response to this application;
- authorise the Company to place the name(s) of the underlying applicant(s) on the register of members of the Company as the holder(s) of any Hong Kong Offer Shares to be allotted to them, and (subject to the terms and conditions set out in this Application Form) to send any Share certificate(s) by ordinary post at that underlying applicant's own risk to the address stated on this Application Form in accordance with the procedures prescribed in this Application Form and in the Prospectus;
- request that any e-Refund payment instructions be despatched to the application payment bank account where the applicant(s) had paid the application monies from a single bank account;
- request that any refund cheque(s) be made payable to the underlying applicant(s) who had used multiple bank accounts to pay the application monies;
- confirm that each underlying applicant has read the terms and conditions and application procedures set out in this Application Form and in the Prospectus and agrees to be bound by them;
- represent, warrant and undertake that the allotment of or application for the Hong Kong Offer Shares to the underlying applicant or by underlying applicant or for whose benefit this application is made would not require the Company to comply with any requirements under any law or regulation (whether or not having the force of law) of any territory outside Hong Kong; and
- agree that this application, any acceptance of it and the resulting contract, will be governed by and construed in accordance with the laws of Hong Kong.

- 按照招股章程及本申請表格的條款及條件，並在組織章程細則規限下，申請以下數目的香港發售股份；
- 夾附申請香港發售股份所需的全數付款(包括1%經紀佣金、0.003%證監會交易徵費及0.005%聯交所交易費)；
- 確認相關申請人已承諾及同意接納該等相關申請人根據本申請所申請的香港發售股份，或該等相關申請人根據本申請獲分配的任何較少數目的香港發售股份；
- 明白—貴公司、獨家保薦人、獨家全球協調人、聯席賬簿管理人、聯席牽頭經辦人及包銷商將信賴此等聲明及陳述，以決定是否就本申請配發任何香港發售股份；
- 授權 貴公司將相關申請人的姓名/名稱列入 貴公司股東名冊內，作為任何將配發予相關申請人的香港發售股份的持有人，並(在符合本申請表格所載的條款及條件的情況下)根據本申請表格及招股章程所載程序按本申請表格上所示地址以普通郵遞方式寄發任何股票，郵誤風險概由該相關申請人承擔；
- 要求把任何電子退款指示發送到申請人以單一銀行賬戶繳交申請款項之付款賬戶內；
- 要求任何以多個銀行賬戶繳交申請款項之申請人的退款支票以相關申請人為抬頭人；
- 確認各相關申請人已細閱並同意遵守本申請表格及招股章程所載的條款及條件和申請手續；
- 聲明、保證及承諾向相關申請人配發香港發售股份或由相關申請人或為其利益而提出本申請的人士申請香港發售股份，不會引致 貴公司須遵從香港以外任何地區的法律或規例的任何規定(不論是否具法律效力)；及
- 同意本申請、本申請獲接納以及由此訂立的合同，將受香港法律管轄及按其詮釋。

Signature: 簽名:

Name of applicant: 申請人姓名:

Date: 日期:

Capacity: 身份:

2 We, on behalf of the underlying applicants, offer to purchase 吾等(代表相關申請人)提出認購

Total number of Shares 股份總數	
-----------------------------	--

Hong Kong Offer Shares on behalf of the underlying applicants whose details are contained in the read-only CD-ROM submitted with this Application Form. 香港發售股份(代表相關申請人，其詳細資料載於連同本申請表格遞交的唯讀光碟)

3 Total number of cheques 支票總數

支票總數		cheque(s) 張支票	
are enclosed for a total sum of 其總金額為	HK\$		港元

Cheque number(s) 支票編號

支票編號	
------	--

4 Please use BLOCK letters 請用正楷填寫

Name of White Form eIPO Service Provider 白表eIPO服務供應商名稱	White Form eIPO Service Provider ID 白表eIPO服務供應商編號		
Chinese Name 中文名稱			
Name of contact person 聯絡人士姓名	Contact number 聯絡電話號碼	Fax number 傳真號碼	
Address 地址	For Broker use 此欄供經紀填寫 Lodged by 申請由以下經紀遞交		
	Broker no. 經紀號碼		
	Broker's chop 經紀印章		

For bank use 此欄供銀行填寫

HONG KONG PUBLIC OFFERING — White Form eIPO Service Provider Application Form 香港公開發售 — 白表 eIPO 服務供應商申請表格
Please use this form if you are a White Form eIPO Service Provider and are applying for Hong Kong Offer Shares on behalf of underlying applicants.
倘閣下為白表 eIPO 服務供應商，並代表相關申請人申請認購香港發售股份，請使用本表格。

GUIDE TO COMPLETING THIS APPLICATION FORM

References to boxes below are to the numbered boxes on this Application Form.

1 Sign and date the Application Form in Box 1. Only a written signature will be accepted.

The name and the representative capacity of the signatory should also be stated.

To apply for Hong Kong Offer Shares using this Application Form, you must be named in the list of **White Form eIPO Service Providers** who may provide **White Form eIPO** services in relation to the Hong Kong Public Offering, which was released by the SFC.

2 Put in Box 2 (in figures) the total number of Hong Kong Offer Shares for which you wish to apply on behalf of the underlying applicants.

Applicant details of the underlying applicants on whose behalf you are applying must be contained in one data file in read-only CD-ROM format submitted together with this Application Form.

3 Complete your payment details in Box 3.

You must state in this box the number of cheques you are enclosing together with this Application Form; and you must state on the reverse of each of those cheques (i) your **White Form eIPO Service Provider ID** and (ii) the file number of the data file containing application details of the underlying applicant(s).

The dollar amount(s) stated in this box must be equal to the amount payable for the total number of Hong Kong Offer Shares applied for in Box 2.

All cheque(s) and this Application Form together with a sealed envelope containing the CD-ROM, if any, must be placed in the envelope bearing your company chop.

For payments by cheque, the cheque must:

- be in Hong Kong dollars;
- be drawn on a Hong Kong dollar bank account in Hong Kong;
- show your (or your nominee's) account name;
- be made payable to "Ting Hong Nominees Limited — China Pioneer Pharma Public Offer";
- be crossed "Account Payee Only";
- not be post dated; and
- be signed by the authorised signatories of the **White Form eIPO Services Provider**.

Your application may be rejected if any of these requirements is not met or if the cheque is dishonoured on its first presentation.

It is your responsibility to ensure that details on the cheque(s) submitted correspond with the application details contained in the CD-ROM or data file submitted in respect of this application. The Company and the Global Coordinator have full discretion to reject any applications in the case of discrepancies.

No receipt will be issued for sums paid on application.

4 Insert your details in Box 4 (using BLOCK letters).

You should write the name, ID and address of the **White Form eIPO Service Provider** in this box. You should also include the name and telephone number of the contact person at your place of business and where applicable, the Broker No. and Broker's Chop.

Personal Information Collection Statement

The main provisions of the Personal Data (Privacy) Ordinance (the "Ordinance") came into effect in Hong Kong on 20 December 1996. This Personal Information Collection Statement informs the applicants for and holders of the Shares of the policies and practices of the Company and the Hong Kong Share Registrar in relation to personal data and the Ordinance.

1. Reasons for the collection of your personal data

From time to time it is necessary for applicants for securities or registered holders of securities to supply their latest correct personal data to the Company and/or the Hong Kong Share Registrar when applying for securities or transferring securities into or out of their names or in procuring the services of the Hong Kong Share Registrar.

Failure to supply the requested data may result in your application for securities being rejected or in delay or inability of the Company and/or the Hong Kong Share Registrar to effect transfers or otherwise render their services. It may also prevent or delay registration or transfer of the Hong Kong Offer Shares which you have successfully applied for and/or the despatch of share certificate(s), and/or the despatch of e-Refund payment instructions and/or the despatch of refund cheque(s) to which you are entitled.

It is important that holders of securities inform the Company and the Hong Kong Share Registrar immediately of any inaccuracies in the personal data supplied.

2. Purposes

The personal data of the holders of securities may be used, held and/or stored (by whatever means) for the following purposes:

- processing of your application and e-Refund payment instructions/refund cheque, where applicable, and verification of compliance with the terms and application procedures set out in this form and the Prospectus;
- registering new issues or transfers into or out of the names of holders of securities including, where applicable, in the name of HKSCC Nominees;
- maintaining or updating the registers of holders of securities of the Company;
- conducting or assisting to conduct signature verifications, any other verification or exchange of information;
- establishing benefit entitlements of holders of securities of the Company, such as dividends, rights issues and bonus issues, etc;
- distributing communications from the Company and its subsidiaries;
- compiling statistical information and Shareholder profiles;
- making disclosures as required by laws, rules or regulations;
- disclosing identities of successful applicants by way of press announcement(s) or otherwise;
- disclosing relevant information to facilitate claims on entitlements; and
- any other incidental or associated purposes relating to the above and/or to enable the Company and the Hong Kong Share Registrar to discharge their obligations to holders of securities and/or regulators and any other purpose to which the holders of securities may from time to time agree.

3. Transfer of personal data

Personal data held by the Company and the Hong Kong Share Registrar relating to the holders of securities will be kept confidential but the Company and the Hong Kong Share Registrar may, to the extent necessary for achieving the above purposes or any of them, make such enquiries as they consider necessary to confirm the accuracy of the personal data and in particular, they may disclose, obtain, transfer (whether within or outside Hong Kong) the personal data of the holders of securities to, from or with any and all of the following persons and entities:

- the Company or its appointed agents such as financial advisers, receiving bankers and overseas principal registrars;
- where applicants for securities request deposit into CCASS, to HKSCC and HKSCC Nominees, who will use the personal data for the purposes of operating CCASS;
- any agents, contractors or third-party service providers who offer administrative, telecommunications, computer, payment or other services to the Company and/or the Hong Kong Share Registrar in connection with the operation of their respective businesses;
- the Stock Exchange, the SFC and any other statutory, regulatory or governmental bodies; and
- any other persons or institutions with which the holders of securities have or propose to have dealings, such as their bankers, solicitors, accountants or stockbrokers, etc.

4. Access and correction of personal data

The Ordinance provides the holders of securities with rights to ascertain whether the Company or the Hong Kong Share Registrar hold their personal data, to obtain a copy of that data, and to correct any data that is inaccurate. In accordance with the Ordinance, the Company and the Hong Kong Share Registrar have the right to charge a reasonable fee for the processing of any data access request. All requests for access to data or correction of data or for information regarding policies and practices and the kinds of data held should be addressed to the Company for the attention of the Company secretary or (as the case may be) the Hong Kong Share Registrar for the attention of the Privacy Compliance Officer for the purposes of the Ordinance.

By signing this form, you agree to all of the above.

填寫本申請表格的指引

下文提述的號碼乃本申請表格中各欄的編號。

1 在申請表格欄1簽署及填上日期。只接受親筆簽名。

簽署人的姓名／名稱及代表身份亦必須註明。

如要使用本申請表格申請香港發售股份，閣下必須為名列於證監會公佈的白表eIPO服務供應商名單可就香港公開發售提供白表eIPO服務的人士。

2 在欄2填上閣下欲代表相關申請人申請認購的香港發售股份總數(以數字填寫)。

閣下代其作出申請的相關申請人資料，必須載於連同本申請表格遞交的唯一光碟內的一個資料檔案。

3 在欄3填上閣下付款的詳細資料。

閣下必須在本欄註明閣下連同本申請表格夾附的支票數目；及閣下必須在每張支票的背面註明(i) 閣下的白表eIPO服務供應商身份證明號碼及(ii)載有相關申請人的申請詳細資料的資料檔案的檔案編號。

本欄所註明的金額必須與欄2所申請認購的香港發售股份總數應付的金額相同。

所有支票及本申請表格，連同載有該光碟(如有)的密封信封必須放進蓋上閣下公司印章的信封內。

如以支票繳付股款，該支票必須：

- 為港元支票；
- 由在香港開設的港元銀行賬戶付款；
- 顯示閣下(或閣下代名人)的賬戶名稱；
- 註明抬頭人為「鼎康代理有限公司 — 中國先鋒醫藥公開發售」；
- 以「只准入抬頭人賬戶」劃線方式開出；
- 不得為期票；及
- 由白表eIPO服務供應商的授權簽署人簽署。

倘未能符合任何此等規定或倘支票首次過戶不獲兌現，閣下的申請可遭拒絕受理。

閣下有責任確保所遞交的支票上的詳細資料，與就本申請遞交的光碟或資料檔案所載的申請詳細資料相同。倘出現差異，本公司及全球協調人可全權酌情拒絕接受任何申請。

申請時繳付的款項將不會獲發收據。

4 在欄4填上閣下的詳細資料(用正楷字母填寫)。

閣下必須在本欄填上白表eIPO服務供應商的名稱、身份證明號碼及地址。閣下亦必須填寫閣下營業地點的聯絡人士的姓名及電話號碼及(如適用)經紀號碼及蓋上經紀印章。

個人資料收集聲明

個人資料(私隱)條例(「條例」)中之主要條文於一九九六年十二月二十日在香港生效。此份個人資料收集聲明是向股份申請人及持有人說明本公司及其香港證券登記處就個人資料及條例而制訂之政策及措施。

1. 收集閣下個人資料之原因

證券申請人或證券登記持有人申請證券或將證券轉往其名下，或將名下證券轉讓予他人，或要求香港證券登記處提供服務時，須不時向本公司及／或香港證券登記處提供其最新之準確個人資料。

若未能提供所需資料，可能會導致閣下之證券申請遭拒絕或本公司及／或香港證券登記處延遲或不能辦理閣下之證券過戶或提供其他服務，亦可能妨礙或延誤閣下成功申請之香港發售股份之登記或過戶及／或妨礙或延誤寄發股票及／或發送任何電子退款指示及／或寄發閣下應得之退款支票。

證券持有人提供之個人資料如有任何不確，必須即時知會本公司及香港證券登記處。

2. 資料用途

證券持有人之個人資料可以任何方式被採用、持有及／或保存，以作下列用途：

- 處理閣下之申請及電子退款指示／退款支票(如適用)及核實是否遵守本表格及招股章程所載條款及申請手續；
- 為證券持有人登記新發行證券或轉往其名下或由其名下轉讓予他人之證券，包括(如適用)以香港結算代理人之名義登記；
- 保存或更新本公司證券持有人名冊；
- 核對或協助核對簽名、核對或交換任何其他資料；
- 確定本公司證券持有人可獲取股息、供股及紅股等利益的資格；
- 寄發本公司及其附屬公司之公司通訊；
- 編製統計資料及股東資料；
- 遵照法例、規則或規例之要求作出披露；
- 透過報章公佈或其他方式披露成功申請人士之身份；
- 披露有關資料以便作出權益索償；及
- 與上述有關之任何其他附帶或相關用途及／或致使本公司及香港證券登記處能履行其對證券持有人及／或監管機構之責任及證券持有人不時同意之任何其他用途。

3. 轉交個人資料

本公司及香港證券登記處會將證券持有人之個人資料保密，但本公司及香港證券登記處可能會就上述用途作出其視為必要之查詢以確定個人資料之準確性，尤其可能會向下列任何及所有人士及機構披露、獲取或轉交證券持有人之個人資料(不論在香港或外地)：

- 本公司或其委任之代理，例如財務顧問、收款銀行及海外主要過戶登記處；
- 倘申請人要求將證券存入中央結算系統，則包括在運作中央結算系統方面須使用個人資料之香港結算及香港結算代理人；
- 任何向本公司及／或香港證券登記處提供與其各自業務運作有關之行政、電訊、電腦、付款或其他服務之代理、承辦商或第三方服務供應商；
- 聯交所、證監會及任何其他法定、監管或政府機關；及
- 與證券持有人有或擬有業務往來之任何其他人士或機構，例如銀行、律師、會計師或股票經紀等。

4. 查閱及更正個人資料

條例賦予證券持有人權利以確定本公司或香港證券登記處是否持有其個人資料、索取有關資料副本及更正任何不確之資料。根據條例規定，本公司及香港證券登記處有權就處理任何查閱資料之要求收取合理費用。所有關於查閱資料或更正資料或索取關於政策及措施及所持有資料類別的資料之要求，應向本公司之公司秘書或(視乎情況而定)香港證券登記處屬下條例所指之私隱權條例事務主任提出。

閣下簽署本申請表格，即表示同意上述所有規定。

DELIVERY OF THIS APPLICATION FORM

This completed Application Form, together with the appropriate cheque(s) together with a sealed envelope containing the CD-Rom must be submitted to the following addresses by 4:00 p.m. on Tuesday, 29 October 2013:

DBS Bank (Hong Kong) Limited

12th Floor, One Island East, 18 Westlands Road, Island East, Hong Kong

遞交本申請表格

經填妥的申請表格，連同相關支票及載有光碟的密封信封，必須於二零一三年十月二十九日(星期二)下午四時正之前，送達下列地址：

星展銀行(香港)有限公司

香港港島東華蘭路18號港島東中心12樓